|Bid||138.71 x 100|
|Ask||138.83 x 100|
|Day's Range||133.40 - 139.00|
|52 Week Range||96.18 - 145.42|
|PE Ratio (TTM)||65.71|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
On a per-share basis, the New Haven, Connecticut-based company said it had profit of 73 cents. Earnings, adjusted for one-time gains and costs, were $1.56 per share. The results beat Wall Street expectations. ...
Q2 2017 Alexion Pharmaceuticals Inc Earnings Call
Shares of Alexion Pharmaceuticals (ALXN) are rising today after the biotech company beat earnings forecasts and raised its guidance. Leerink analyst Geoffrey Porges and Bradley Canino call today's report "the most important" of the large-cap biotech stocks: This morning Alexion announced Q2 revenue of $912mm, which was a 7% beat against consensus of $849mm and an 8% beat vs. our estimate of $846mm (which implied sequentially lower revenue given management’s conservative commentary last quarter and the attrition of patients on Soliris to clinical trials). Shares of Alexion Pharmaceuticals have gained 2% to $133.72 at 12:18 p.m. today, but had been up as much as 8.6% earlier today.